Afatinib (Giotrif®) : The 1st choice in 1st-line

Afatinib: The 1st line choice in sequential therapy of NSCLC

 
 

RESET study showed the feasibility of sequential treatment in patients with EGFR-mutated advanced NSCLC, maximizing sustained clinical benefit and minimizing exposure to chemotherapy

Document ID: PC-VN-101786

13/10/2021

Author: Boehringer Ingelheim

123,000
Views

100k 340

NHỮNG NỘI DUNG LIÊN QUAN

 
PC-VN-101786
Production date: October 2021